Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PRNP | P04156 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 7/20 | 0.42 |
| ▸ | CES1 | P23141 | 5/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.40 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.40 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383586 | 1.00 | TDP1 (0.46) | TDP1POLBDAGLARXFP1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5170441 | 0.99 | TDP1 (0.45) | TDP1POLBDAGLARXFP1ALDH1A1 | |
| SCHEMBL5166341 | 0.99 | POLB (0.48) | TDP1POLBDAGLARXFP1ALDH1A1 | |
| SCHEMBL385258 | 0.96 | TDP1 (0.43) | TDP1POLBDAGLARXFP1ALDH1A1 | |
| Maleic Acid SCHEMBL383976 | 0.95 | POLB (0.42) | TDP1POLBDAGLARXFP1ALDH1A1 | |
| Fumaric Acid SCHEMBL383978 | 0.95 | POLB (0.42) | TDP1POLBDAGLARXFP1ALDH1A1 | |
| SCHEMBL5169197 | 0.90 | POLB (0.45) | TDP1POLBRXFP1ALDH1A1LMNA | |
| SCHEMBL5167470 | 0.90 | POLB (0.43) | TDP1POLBRXFP1ALDH1A1LMNA | |
| SCHEMBL6765320 | 0.89 | TDP1 (0.49) | TDP1POLBDAGLARXFP1ALDH1A1 | |
| SCHEMBL6774680 | 0.89 | POLB (0.44) | TDP1POLBDAGLARXFP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2045325-B1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO CO LTD (JP) | 2012-09-19 | — | — | EP | claimed |
| US-20100248227-A1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-09-30 | — | — | US | claimed |
| US-20100081702-A1 | PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF HEPATITIS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | claimed |
| EP-2149549-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF HEPATITIS | Daiichi Sankyo Company, Limited (JP) | 2010-02-03 | — | — | EP | claimed |
| EP-2045325-A1 | DRUG-PHOSPHORYLATING ENZYME | Daiichi Sankyo Company, Limited (JP) | 2009-04-08 | — | — | EP | claimed |
| EP-2045325-B1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO CO LTD (JP) | 2012-09-19 | — | — | EP | disclosed |
| EP-2045325-B1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO CO LTD (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-20100248227-A1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100248227-A1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100248227-A1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100248227-A1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100081702-A1 | PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF HEPATITIS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20100081702-A1 | PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF HEPATITIS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20100081702-A1 | PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF HEPATITIS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| EP-2149549-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF HEPATITIS | Daiichi Sankyo Company, Limited (JP) | 2010-02-03 | — | — | EP | disclosed |
| EP-2149549-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF HEPATITIS | Daiichi Sankyo Company, Limited (JP) | 2010-02-03 | — | — | EP | disclosed |
| EP-2045325-A1 | DRUG-PHOSPHORYLATING ENZYME | Daiichi Sankyo Company, Limited (JP) | 2009-04-08 | — | — | EP | disclosed |
| EP-2045325-A1 | DRUG-PHOSPHORYLATING ENZYME | Daiichi Sankyo Company, Limited (JP) | 2009-04-08 | — | — | EP | disclosed |
| EP-2045325-A1 | DRUG-PHOSPHORYLATING ENZYME | Daiichi Sankyo Company, Limited (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008016133-A1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081702-A1 | PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF HEPATITIS | SLC10A1, C1S, C1R | TDP1 4093/4885POLB 1843/4885DAGLA 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.